粪便DNA中的p33甲基化作为结直肠癌及癌前病变的分子筛查工具
p33 methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions.
作者信息
He Chun-Gang, Huang Qin-Yuan, Chen Li-Sheng, Ling Zhi-An, Wu Hong-Gen, Deng Hong-Qiang
机构信息
Department of General and Pediatric Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Nursing College of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
出版信息
Oncol Lett. 2014 May;7(5):1639-1644. doi: 10.3892/ol.2014.1923. Epub 2014 Feb 28.
The present study aimed to investigate the feasibility of detecting p33 inhibitor of growth 1b (p33) gene methylation in fecal DNA as a screening method for colorectal carcinoma (CRC) and precancerous lesions. The methylation of p33 was analyzed in fecal samples from 61 patients with CRCs, 27 patients with precancerous lesions (advanced adenoma) and 20 normal individuals by nested methylation-specific polymerase chain reaction (nMSP) and fecal occult blood test. Methylated p33 was detected in 73.77% of CRC patients and 62.96% of adenoma patients. By contrast, only 5% of normal individuals had methylated p33. These results indicated 73.77% sensitivity for detecting CRC, 62.96% sensitivity for detecting precancerous lesions and 95% specificity of the assay for detecting CRCs and precancerous lesions. The detection of p33 methylation status by incubation of DNA contained in agarose beads for bisulfite modification, followed by nMSP, is a promising non-invasive screening method for CRCs and precancerous lesions.
本研究旨在探讨检测粪便DNA中生长抑制因子1b（p33）基因甲基化作为结直肠癌（CRC）及癌前病变筛查方法的可行性。采用巢式甲基化特异性聚合酶链反应（nMSP）和粪便潜血试验，对61例CRC患者、27例癌前病变（高级别腺瘤）患者及20例正常个体的粪便样本进行p33甲基化分析。73.77%的CRC患者和62.96%的腺瘤患者检测到p33甲基化。相比之下，仅5%的正常个体检测到p33甲基化。这些结果表明，该检测方法检测CRC的灵敏度为73.77%，检测癌前病变的灵敏度为62.96%，检测CRC和癌前病变的特异性为95%。通过将琼脂糖珠中所含DNA进行亚硫酸氢盐修饰后孵育，随后进行nMSP来检测p33甲基化状态，是一种用于CRC和癌前病变的有前景的非侵入性筛查方法。
Zotero 插件